PUBLISHER: Arizton Advisory & Intelligence | PRODUCT CODE: 1421548
PUBLISHER: Arizton Advisory & Intelligence | PRODUCT CODE: 1421548
The global IV and Oral Iron Drugs market, valued at $7.66 billion in 2023, will experience robust growth by 2029, expanding at a CAGR of 13.47%. This surge is primarily driven by the increasing prevalence of Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) globally, coupled with a heightened awareness among patients about effective treatment options. The market's expansion is further propelled by the rising occurrence of chronic diseases such as Chronic Kidney Disease (CKD), heart failure, gastrointestinal disorders, and cancer, which can lead to iron deficiency, particularly in surgical patients.
Key factors fueling market growth include the growing demand for dextran-free iron therapeutics and the rising need for iron drugs among dialysis and non-dialysis kidney patients. The market also benefits from the development of investigational latest generation IV & oral iron drugs with broader indications and improved treatment outcomes.
Market leaders like Vifor Pharma are significantly contributing with products such as Ferinject (marketed as Injectafer in the US) and Venofer, which are gaining traction, especially among dialysis patients. The oral iron drug segment, comprising both prescription and OTC preparations, is expanding steadily, although slower than IV iron drugs, with significant growth in emerging and low-income countries due to their cost-effectiveness.
The market's growth is not just confined to developed nations; it's also significant in developing countries across Asia, Africa, and Latin America, where iron deficiency poses a severe health challenge. This growth is further augmented by innovations in hospital pharmacy practice and retail store involvement, facilitating accessibility and awareness among consumers.
The hospital pharmacies segment is expected to grow due to their specialized services in iron medicines. At the same time, retail stores continue to play a crucial role due to immediate product availability and expert guidance. The prevalence of iron deficiency in CKD patients, which is estimated to be around 70%, highlights the critical need for iron therapy with IV and oral iron drugs.
As the global IV & oral iron drugs market evolves, key vendors like Vifor Pharma, Daiichi Sankyo Group, AMAG Pharmaceuticals, and others focus on product innovations and expanded label approvals to meet the growing demands and adapt to new patient groups. The market, characterized by the presence of global, regional, and local players, is highly competitive with a wide array of branded and generic drug offerings.
KEY HIGHLIGHTS:
REPORT HIGHLIGHTS
PRODUCT SEGMENTATION & FORECAST
VENDORS LIST
CHAPTER - 1: IV & Oral Iron Drugs Market Overview
CHAPTER - 2: IV & Oral Iron Drugs Market
CHAPTER - 3: IV & Oral Iron Drugs Market Segmentation Data
CHAPTER - 4: Key Regions Overview
CHAPTER - 5: IV & Oral Iron Drugs Market Prospects & Opportunities
CHAPTER - 6: IV & Oral Iron Drugs Industry Overview
CHAPTER - 7: Appendix
Exhibit 1: Projected Revenues of IV & Oral Iron Drugs in Global ($ Bn)
Exhibit 2: Market Size & Forecast - Intravenous ($ Bn)
Exhibit 3: Market Size & Forecast - Oral ($ Bn)
Exhibit 4: Market Size & Forecast - Adults ($ Bn)
Exhibit 5: Market Size & Forecast - Pediatrics ($ Bn)
Exhibit 6: Market Size & Forecast - Hospital Pharmacies ($ Bn)
Exhibit 7: Market Size & Forecast - Offline Retail Stores
Exhibit 8: Market Size & Forecast - Online Channels ($ Bn)
Exhibit 9: Market Size & Forecast - Nephrology ($ Bn)
Exhibit 10: Market Size & Forecast - Obstetrics & Gynecology ($ Bn)
Exhibit 11: Market Size & Forecast - Surgery ($ Bn)
Exhibit 12: Market Size & Forecast - Gastroenterology ($ Bn)
Exhibit 13: Market Size & Forecast - Oncology ($ Bn)
Exhibit 14: Market Size & Forecast - Heart Failure ($ Bn)
Exhibit 17: Projected Revenues of IV & Oral Iron Drugs in North America ($ Bn)
Exhibit 18: Projected Revenues of IV & Oral Iron Drugs in US ($ Bn)
Exhibit 19: Projected Revenues of IV & Oral Iron Drugs in Canada ($ Bn)
Exhibit 20: Projected Revenues of IV & Oral Iron Drugs in Europe ($ Bn)
Exhibit 21: Projected Revenues of IV & Oral Iron Drugs in Germany ($ Bn)
Exhibit 22: Projected Revenues of IV & Oral Iron Drugs in UK ($ Bn)
Exhibit 23: Projected Revenues of IV & Oral Iron Drugs in France ($ Bn)
Exhibit 24: Projected Revenues of IV & Oral Iron Drugs in Italy ($ Bn)
Exhibit 25: Projected Revenues of IV & Oral Iron Drugs in Spain ($ Bn)
Exhibit 26: Projected Revenues of IV & Oral Iron Drugs in APAC ($ Bn)
Exhibit 27: Projected Revenues of IV & Oral Iron Drugs in Japan ($ Bn)
Exhibit 28: Projected Revenues of IV & Oral Iron Drugs in China ($ Bn)
Exhibit 29: Projected Revenues of IV & Oral Iron Drugs in Australia ($ Bn)
Exhibit 30: Projected Revenues of IV & Oral Iron Drugs in Latin America ($ Bn)
Exhibit 31: Projected Revenues of IV & Oral Iron Drugs in Brazil ($ Bn)
Exhibit 32: Projected Revenues of IV & Oral Iron Drugs in Mexico ($ Bn)
Exhibit 33: Projected Revenues of IV & Oral Iron Drugs in Argentina ($ Bn)
Exhibit 34: Projected Revenues of IV & Oral Iron Drugs in Middle East & Africa ($ Bn)
Exhibit 35: Projected Revenues of IV & Oral Iron Drugs in Turkey ($ Bn)
Exhibit 36: Projected Revenues of IV & Oral Iron Drugs in South Africa ($ Bn)
Exhibit 37: Projected Revenues of IV & Oral Iron Drugs in Saudi Arabia ($ Bn)
LIST OF TABLES
Table 1: Key Market Trends in IV & Oral Iron Drugs Market
Table 2: Key Market Enablers in IV & Oral Iron Drugs Market
Table 3: Key Market Constraints in IV & Oral Iron Drugs Market
Table 4: Strategic Recommendations in IV & Oral Iron Drugs Market